Cargando…
Ofatumumab‐associated acute pneumonitis: Not new but still the first case
Ofatumumab is an anti‐CD20 humanized monoclonal antibody utilized in the treatment of several clinical conditions resistant to other treatments. In spite there was a general expectation that ofatumumab was less toxic compared to rituximab, side effects have been reported that resemble those of its a...
Autores principales: | Bonanni, Alice, Bertelli, Enrica, Panicucci, Chiara, D'Alessandro, Matteo, Moscatelli, Andrea, Lampugnani, Elisabetta, Sacco, Oliviero, Magnano, Gian Michele, Ravani, Pietro, Ghiggeri, Gian Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461639/ https://www.ncbi.nlm.nih.gov/pubmed/28596831 http://dx.doi.org/10.1002/prp2.267 |
Ejemplares similares
-
Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol
por: Ravani, Pietro, et al.
Publicado: (2017) -
A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome
por: Bonanni, Alice, et al.
Publicado: (2015) -
LPS Nephropathy in Mice Is Ameliorated by IL-2 Independently of Regulatory T Cells Activity
por: Bertelli, Roberta, et al.
Publicado: (2014) -
Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease
por: Bertelli, Roberta, et al.
Publicado: (2018) -
Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)